PRTK

Paratek Pharmaceuticals, Inc. [PRTK] Stock Forecast

Q: What is Paratek Pharmaceuticals, Inc. stock symbol ?

Paratek Pharmaceuticals, Inc. is a US stock, located in Boston of Ma and trading under the symbol PRTK

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

PRTK Stock Summary

Earnings have grown 24.67% per last year.

EPS has been increasing for the past 3 years (Yearly statements)

The Moving Average Convergence Divergence (MACD) for PRTK recently turned positive (within last 10 days).

Earnings are expected to fall -100% next year

PRTK has less than 1 year of cash runway

In the News

PRTK Financial details

Company Rating

Neutral

Market Cap

127.83M

Income

-67.12M

Revenue

167.74M

Book val./share

-3.52

Cash/share

0.75

Dividend

Dividend %

Employees

268

Optionable

Shortable

Yes

Earnings

01 Nov 2023

P/E

-1.9

Forward P/E

PEG

7.73

P/S

0.76

P/B

-0.63

P/C

P/FCF

-5.49

Quick Ratio

0.42

Current Ratio

0.52

Debt / Equity

-1.29

LT Debt / Equity

-0.48

EPS (TTM)

-1.19

EPS next Y

EPS next Q

EPS this Y

-4.1%

EPS next Y

EPS next 5Y

EPS last 5Y

-20%

Revenue last 5Y

54.52%

Revenue Q/Q

30.31%

EPS Q/Q

-28.57%

SMA20

SMA50

SMA100

Inst Own

37.04%

Inst Trans

0.91%

ROA

-46%

ROE

37%

ROC

0.78%

Gross Margin

85%

Oper. Margin

-27%

Profit Margin

-40%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

1.29-3.65

52W High

52W Low

RSI

Rel Volume

7.46

Avg Volume

599.68K

Volume

Perf Week

Perf Month

Perf Quarter

Perf Half Y

Beta

1.69779

Volatility

0%, 0%

Prev Close

Price

Change

PRTK Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.54	0.5	0.99	2.5	2.77
Net income per share	-3.57	-3.93	-2.63	-1.22	-1.17
Operating cash flow per share	-2.58	-4.09	-2.34	-1	-1.22
Free cash flow per share	-2.58	-4.1	-2.35	-1	-1.22
Cash per share	15.75	6.57	2.83	1.97	0.63
Book value per share	1.51	-1.21	-2.31	-2.64	-3.14
Tangible book value per share	1.48	-1.23	-2.33	-2.66	-3.16
Share holders equity per share	1.51	-1.21	-2.31	-2.64	-3.14
Interest debt per share	7.61	8.52	6.16	5.64	5.08
Market cap	161.66M	132.15M	276.53M	217.39M	101.71M
Enterprise value	97.79M	292.67M	423.4M	392.75M	325.87M
P/E ratio	-1.44	-1.03	-2.38	-3.68	-1.6
Price to sales ratio	9.44	7.99	6.35	1.8	0.67
POCF ratio	-1.99	-0.99	-2.67	-4.5	-1.54
PFCF ratio	-1.99	-0.98	-2.66	-4.47	-1.54
P/B Ratio	3.39	-3.33	-2.7	-1.7	-0.59
PTB ratio	3.39	-3.33	-2.7	-1.7	-0.59
EV to sales	5.71	17.69	9.73	3.25	2.16
Enterprise value over EBITDA	-0.97	-2.61	-5.73	-9.65	-7.26
EV to operating cash flow	-1.2	-2.18	-4.09	-8.14	-4.93
EV to free cash flow	-1.2	-2.18	-4.08	-8.07	-4.92
Earnings yield	-0.69	-0.97	-0.42	-0.27	-0.63
Free cash flow yield	-0.5	-1.02	-0.38	-0.22	-0.65
Debt to equity	4.8	-6.62	-2.46	-2	-1.51
Debt to assets	0.76	1.05	1.43	1.39	1.5
Net debt to EBITDA	0.63	-1.43	-1.99	-4.31	-4.99
Current ratio	14.41	10.06	6.85	4.86	3.66
Interest coverage	-9.48	-7.05	-3.73	-2.36	-2.55
Income quality	0.72	1.04	1.07	0.82	1.04
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	3.72	0	0	0	0
Research and developement to revenue	3.36	2.39	0.55	0.25	0.25
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0.01	0
Capex to revenue	0	-0.01	-0.01	0	0
Capex to depreciation	0.06	0.18	-0.65	-0.95	-0.07
Stock based compensation to revenue	1.49	0.86	0.24	0.12	0.08
Graham number	11.02	10.35	11.71	8.51	9.09
ROIC	-0.38	-0.51	-0.6	-0.32	-0.52
Return on tangible assets	-0.38	-0.51	-0.66	-0.32	-0.37
Graham Net	7.07	-1.9	-3.05	-3.84	-4.46
Working capital	237.53M	219.15M	140.16M	120.8M	99.45M
Tangible asset value	46.75M	-40.48M	-103.09M	-128.62M	-171.87M
Net current asset value	2.63M	-47.37M	-115M	-159.56M	-206.74M
Invested capital	4.8	-6.62	-2.46	-2	-1.51
Average receivables	3.07M	4.92M	12.66M	24.43M	55.58M
Average payables	2.82M	3.1M	2.96M	3.6M	5.35M
Average inventory	-21.03M	-15.32M	13.07M	12.79M	13.79M
Days sales outstanding	5.31	211.42	131.96	99.94	188.9
Days payables outstanding	0	431.21	76.49	91.42	84.03
Days of inventory on hand	0	1.21K	614.1	186.78	262.24
Receivables turnover	68.74	1.73	2.77	3.65	1.93
Payables turnover	0	0.85	4.77	3.99	4.34
Inventory turnover	0	0.3	0.59	1.95	1.39
ROE	-2.36	3.24	1.14	0.46	0.37
Capex per share	0	-0.01	-0.01	-0.01	0

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2022-06-30	2022-09-30	2022-12-31	2023-03-31	2023-06-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.52	0.5	1.34	0.51	0.66
Net income per share	-0.42	-0.46	-0.13	-0.35	-0.25
Operating cash flow per share	-0.27	-0.23	-0.37	0.19	-0.03
Free cash flow per share	-0.27	-0.23	-0.37	0.19	-0.03
Cash per share	1.31	1.03	0.63	0.79	0.75
Book value per share	-2.82	-3.01	-3.14	-3.32	-3.52
Tangible book value per share	-2.83	-3.03	-3.16	-3.34	-3.53
Share holders equity per share	-2.82	-3.01	-3.14	-3.32	-3.52
Interest debt per share	4.95	4.78	4.84	4.63	4.63
Market cap	102.34M	141.78M	101.71M	144.53M	126.59M
Enterprise value	320.84M	373.79M	325.87M	358.58M	343.66M
P/E ratio	-1.16	-1.4	-3.55	-1.79	-2.17
Price to sales ratio	3.71	5.09	1.4	4.95	3.33
POCF ratio	-7.06	-11.42	-5.06	13.03	-71.28
PFCF ratio	-7.06	-11.42	-5.05	13.07	-71.28
P/B Ratio	-0.69	-0.85	-0.59	-0.76	-0.63
PTB ratio	-0.69	-0.85	-0.59	-0.76	-0.63
EV to sales	11.64	13.42	4.49	12.28	9.03
Enterprise value over EBITDA	-24.79	-23.05	-132.68	-23.05	-37.48
EV to operating cash flow	-22.13	-30.1	-16.2	32.33	-193.5
EV to free cash flow	-22.13	-30.1	-16.17	32.43	-193.5
Earnings yield	-0.22	-0.18	-0.07	-0.14	-0.11
Free cash flow yield	-0.14	-0.09	-0.2	0.08	-0.01
Debt to equity	-1.73	-1.56	-1.51	-1.37	-1.29
Debt to assets	1.58	1.65	1.5	1.72	1.78
Net debt to EBITDA	-16.88	-14.31	-91.27	-13.76	-23.67
Current ratio	4.24	3.11	3.66	3.39	0.52
Interest coverage	-2.9	-3.64	-0.62	-3.53	-1.78
Income quality	0.82	0.59	2.81	-0.55	0.12
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.28	0.3	0.2	0.25	0.23
Intangibles to total assets	0.01	0.01	0	0.01	0.01
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	-0.42	-0.68	0
Stock based compensation to revenue	0.14	0.14	0.03	0.07	0.06
Graham number	5.14	5.57	3.05	5.14	4.48
ROIC	-0.15	-0.21	-0.03	-0.22	-0.16
Return on tangible assets	-0.14	-0.16	-0.04	-0.13	-0.1
Graham Net	-4.02	-4.2	-4.46	-4.57	-4.66
Working capital	97.67M	82.37M	99.45M	78.27M	-97.39M
Tangible asset value	-150.2M	-166.98M	-171.87M	-189.87M	-202.19M
Net current asset value	-185.29M	-202.13M	-206.74M	-228.85M	-241.93M
Invested capital	-1.73	-1.56	-1.51	-1.37	-1.29
Average receivables	30.04M	32.28M	55.39M	57.6M	39.84M
Average payables	3.48M	5.18M	6.71M	5.31M	4.13M
Average inventory	12.91M	16.92M	18.66M	15.28M	12.7M
Days sales outstanding	103.92	105.82	96.71	114.52	100.52
Days payables outstanding	41.64	166.89	46.33	76.65	60.8
Days of inventory on hand	241.38	427.15	144.57	201.64	235.16
Receivables turnover	0.87	0.85	0.93	0.79	0.9
Payables turnover	2.16	0.54	1.94	1.17	1.48
Inventory turnover	0.37	0.21	0.62	0.45	0.38
ROE	0.15	0.15	0.04	0.11	0.07
Capex per share	0	0	0	0	0

PRTK Frequently Asked Questions

What is Paratek Pharmaceuticals, Inc. stock symbol ?

Paratek Pharmaceuticals, Inc. is a US stock , located in Boston of Ma and trading under the symbol PRTK

What is Paratek Pharmaceuticals, Inc. stock quote today ?

Paratek Pharmaceuticals, Inc. stock price is $- today.

Is Paratek Pharmaceuticals, Inc. stock public?

Yes, Paratek Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Check Those

Similar Market Cap

Company Profile

Volume Average 599.68K
Market Capitalization 127.83M
Employee 268
CEO Dr. Evan Loh FACC, FAHA, M.D.
Headquarters Boston,MA,US
IPO Date 2009-02-03
Website https://paratekpharma.com

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.